Inmune Fundamentals

INMB
 Stock
  

USD 9.41  0.29  3.18%   

Inmune Bio fundamentals help investors to digest information that contributes to Inmune Bio's financial success or failures. It also enables traders to predict the movement of Inmune Stock. The fundamental analysis module provides a way to measure Inmune Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inmune Bio stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Inmune Bio Operating Expenses is projected to increase significantly based on the last few years of reporting. The past year's Operating Expenses was at 29.33 Million. The current year Research and Development Expense is expected to grow to about 22.2 M, whereas Consolidated Income is forecasted to decline to (31.1 M).

Inmune Return On Equity Analysis

Inmune Bio's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
 2010 2021 2022 (projected)
Revenues USD11 K181 K150.84 K
Revenues11 K181 K150.84 K
Return on Equity 
 = 
Net Income 
Total Equity 
X
100 
More About Return On Equity | All Equity Analysis

Current Inmune Bio Return On Equity

    
  (46.96) %  
Most of Inmune Bio's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Compare to competition

Inmune Shareholders Equity

Shareholders Equity

86.56 Million

Inmune Bio Shareholders Equity is projected to increase significantly based on the last few years of reporting. The past year's Shareholders Equity was at 80.22 Million
Based on the latest financial disclosure, Inmune Bio has a Return On Equity of -46.96%. This is 95.91% higher than that of the Healthcare sector and 28.8% higher than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.

Inmune Bio Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Inmune Bio's current stock value. Our valuation model uses many indicators to compare Inmune Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inmune Bio competition to find correlations between indicators driving Inmune Bio's intrinsic value. More Info.
Inmune Bio is currently regarded as number one stock in number of shares shorted category among related companies. It is currently regarded as number one stock in return on asset category among related companies . The current year Average Assets is expected to grow to about 90.1 M. The current year Tangible Asset Value is expected to grow to about 90 M. Comparative valuation analysis is a catch-all model that can be used if you cannot value Inmune Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inmune Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inmune Bio's earnings, one of the primary drivers of an investment's value.

Inmune Price to Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inmune Bio's direct or indirect competition against its Price to Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inmune Bio could also be used in its relative valuation, which is a method of valuing Inmune Bio by comparing valuation metrics of similar companies.
Inmune Bio is currently under evaluation in price to earning category among related companies.

Inmune Bio Current Valuation Drivers

We derive many important indicators used in calculating different scores of Inmune Bio from analyzing Inmune Bio's financial statements. These drivers represent accounts that assess Inmune Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inmune Bio's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Earnings before Tax(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Free Cash Flow(761.83 K)(2.06 M)(5.38 M)(8.94 M)(28.5 M)(29.25 M)
Invested Capital219.04 K(160.63 K)428.87 K559 K19.5 M21.04 M
Tangible Asset Value1.9 M849.34 K7.96 M24.14 M83.43 M90.02 M
Working Capital1.59 M25.58 K7.06 M22.21 M78.25 M84.42 M

Inmune Fundamentals

About Inmune Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Revenues181 K150.8 K
Revenue to Assets 0.001811  0.001954 
Revenue Per Employee18.1 K19.5 K
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Inmune Bio Investors Sentiment

The influence of Inmune Bio's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Inmune. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Inmune Bio's public news can be used to forecast risks associated with investment in Inmune. The trend in average sentiment can be used to explain how an investor holding Inmune can time the market purely based on public headlines and social activities around Inmune Bio. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Inmune Bio's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Inmune Bio's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Inmune Bio's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Inmune Bio.

Inmune Bio Implied Volatility

    
  251.5  
Inmune Bio's implied volatility exposes the market's sentiment of Inmune Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inmune Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inmune Bio stock will not fluctuate a lot when Inmune Bio's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inmune Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inmune Bio's short interest history, or implied volatility extrapolated from Inmune Bio options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Inmune Bio Piotroski F Score and Inmune Bio Altman Z Score analysis. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
168.9 M
Quarterly Revenue Growth YOY
39.75
Return On Assets
-0.26
Return On Equity
-0.58
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.